ArticleJournal of Cancer2022

LPCAT1 promotes gefitinib resistance via upregulation of the EGFR/PI3K/AKT signaling pathway in lung adenocarcinoma.

Jianghua Ding et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.